Background: Long intergenic non-coding RNA 00511 (LINC00511) is highly expressed in diverse cancers and has a correlation with poor clinical outcomes for cancer patients. In view of contradictory data among published data, we aim to evaluate the prognostic role of LINC00511 for cancer patients. Methods: In the present study, a meta-analysis of related studies has been performed to investigate the prognostic significance of LINC00511 in cancer patients. Relevant studies published before December 22, 2019 were systematically searched online in PubMed, EMBASE, Web of Science, and the Cochrane Library databases. The relationship between LINC00511 expression and cancer patients’ survival, including overall survival (OS), disease-free survival (DFS)/relapse-free survival (RFS) and progression-free survival (PFS), was evaluated using pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). The association between LINC00511 expression and clinicopathological features was assessed using odd ratios (ORs) and their corresponding 95% CIs. Results: A total of 14 eligible studies with 1883 patients were enrolled in the present meta-analysis. The results demonstrated that elevated expression of LINC00511 was significantly associated with poor OS (HR = 2.62; 95% CI: 2.00–3.45; p < 0.001), PFS (HR = 1.80; 95% CI: 1.29–2.51; p = 0.001) and DFS/RFS (HR = 2.90; 95% CI: 1.04–8.12; p = 0.04). Additionally, High LINC00511 expression was associated with large tumor size (OR = 3.10; 95% CI: 1.97–4.86; p < 0.00001), lymph node metastasis (OR = 3.11; 95% CI: 2.30–4.21; p < 0.00001), advanced clinical stage (OR = 3.95; 95% CI: 2.68–5.81; p < 0.00001), distant metastasis (OR = 2.39; 95% CI: 1.16–4.93; p = 0.02), and disease recurrence (OR = 4.62; 95% CI: 2.47–8.65; p < 0.00001). Meanwhile, no correlation was found between LINC00511 expression and age, gender, and histological grade. These findings were consolidated by the results of bioinformatics analysis. Conclusions: Based on our findings, LINC00511 may serve as a novel prognostic biomarker for cancer patients.